Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MBIO vs DARE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MBIO Captures Overall Composite Edge (42.9 HOLD vs 45.7 HOLD), While DARE Leads 3–1 on Growth & Valuation Pillars

MBIO Overall Winner 6-Pillar Tally: MBIO 1 – 3 DARE (2 Tie) Matrix Metrics: MBIO 3 – 5 DARE

As of Nov 16, 2026, Mustang Bio, Inc. (MBIO) captures the overall head-to-head institutional edge over Dare Bioscience, Inc. (DARE) on higher Unified Composite conviction (42.9/100 HOLD vs. 45.7/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality), while DARE wins 3–1 across the 6-pillar growth and valuation breakdown. MBIO trades at $0.39 (N/M Forward P/E, 0.0% operating margin) versus DARE at $0.58 (1.3x Forward P/E, -813.4% operating margin).

  • Composite vs. Pillar Nuance: While DARE currently prints a higher short-term Unified Composite Score (45.7/100 HOLD vs. MBIO 42.9/100 HOLD), MBIO captures the overall institutional head-to-head verdict (3–5 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -813.4% operating margin) and revenue trajectory (+0.0% vs. +499.6% YoY).
  • Technical & Structure Timing Caution: MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4); meanwhile DARE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MBIO vs DARE
MBIO NASDAQ Head-to-Head Winner
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-6.34% 1D
Market Cap $3.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.66β · 86% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.4 · SMA20: $0.40 · SMA50: $0.44
DARE NASDAQ
Dare Bioscience, Inc. Common Stock
Pharmaceutical Preparations
$0.58
-11.13% 1D
Market Cap $12.9M
TTM Revenue $1.4M
Forward P/E 1.3x
Beta / 30D Vol 1.40β · 62% Vol
Unified Composite Score
45.7 / 100 HOLD
Tech 33.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.9%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $0.66 · SMA50: $0.73

6-Pillar Scorecard Institutional Category Breakdown (MBIO 1 – 3 DARE)

Columns: Metric · MBIO · DARE
1. Valuation Multiples DARE
Forward P/E N/M 1.3x
Trailing P/E N/M 1.3x
PEG Ratio N/M N/M
EV / Revenue N/M 1.0x
2. Growth & Scale DARE
Revenue Growth (YoY) +0.0% +499.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $1.4M
Market Cap $3.2M $12.9M
3. Profitability & Quality MBIO
Gross Margin N/A N/A
Operating Margin 0.0% -813.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -43.1% -2543.1%
4. Balance Sheet & Cash Flow DARE
Cash Generation (TTM) N/A -$12M
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.87 Book/Sh · -43.1% ROE $12M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MBIO (3) vs DARE (5)
Institutional Metric MBIO DARE Criterion Row Edge
Market Capitalization
Scale
$3.2M $12.9M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M 1.3x Lower Multiple DARE
Forward P/E Ratio
Valuation
N/M 1.3x Lower Multiple DARE
Revenue Growth (YoY)
Growth
+0.0% +499.6% Higher Growth DARE
Operating Margin (TTM)
Profitability
0.0% -813.4% Higher Margin MBIO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-43.1% -2543.1% Higher ROE MBIO
52-Week Range Position
Momentum
4% ($0–$1) 0% ($1–$4) Stronger Trend MBIO
Beta / 30D Volatility
Risk Regime
0.66β · 86% Vol 1.40β · 62% Vol Lower Realized Risk DARE
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 45.7 / 100 (HOLD) Higher Composite DARE
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($0.87 Book/Sh · -43.1% ROE) -$12M ($12M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MBIO +24.24 pp
MBIO: +4.86% · DARE: -19.38%
3M Horizon DARE +6.8 pp
MBIO: -30.75% · DARE: -23.95%
6M Horizon MBIO +38.32 pp
MBIO: -33.99% · DARE: -72.31%
1Y Horizon MBIO +1.71 pp
MBIO: -67.38% · DARE: -69.09%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs DARE. Trailing 12-month operating profitability (MBIO 0.0% vs DARE -813.4%) and valuation multiples (MBIO N/M vs DARE 1.3x Forward P/E) are benchmarked directly in Pillar 4 below.

MBIO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-43.1% · N/M
DARE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.4M
Gross MarginN/A
Op. Margin-813.4%
ROE / Fwd P/E-2543.1% · 1.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DARE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DARE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DARE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $12.9M market capitalization and -813.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MBIO vs DARE Key Questions & Quantitative Answers

As of Nov 16, 2026, Mustang Bio, Inc. (MBIO) captures the overall head-to-head institutional edge over Dare Bioscience, Inc. (DARE) on higher Unified Composite conviction (42.9/100 HOLD vs. 45.7/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality), while DARE wins 3–1 across the 6-pillar growth and valuation breakdown. MBIO trades at $0.39 (N/M Forward P/E, 0.0% operating margin) versus DARE at $0.58 (1.3x Forward P/E, -813.4% operating margin). Composite vs. Pillar Nuance: While DARE currently prints a higher short-term Unified Composite Score (45.7/100 HOLD vs. MBIO 42.9/100 HOLD), MBIO captures the overall institutional head-to-head verdict (3–5 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -813.4% operating margin) and revenue trajectory (+0.0% vs. +499.6% YoY). Technical & Structure Timing Caution: MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4); meanwhile DARE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DARE leads the Growth & Scale pillar: MBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DARE at +499.6% YoY revenue growth and +0.0% YoY earnings growth on $1.4M TTM revenue (N/A gross margin, -813.4% operating margin). On trailing 12-month operating scale, MBIO generates N/A in USD-normalized revenue versus $1.4M for DARE. In operating R&D and SG&A reinvestment, MBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DARE.

DARE screens cheaper on headline valuation multiples. MBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas DARE trades at 1.3x Forward P/E, 1.3x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBIO (-43.1% ROE) versus DARE (-2543.1% ROE) capital efficiency.

In options market volatility and institutional positioning, MBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.66β · 86% Vol realized risk). By comparison, DARE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.40β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.